Literature DB >> 20222813

Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing.

Richard W Grant1, Deborah J Wexler.   

Abstract

Continuing advances in genetic discovery have uncovered several dozen loci that are associated with Type 2 diabetes, including genetic variants that appear to modify responses to commonly prescribed diabetes medications. The use of an individual's genetic information to guide therapy choices raises the possibility of 'personalized medicine', wherein each patient's treatment plan is tailored based on genotype results. However, before such a model of care can be implemented, research is needed to more clearly quantify the association of genetic variation with treatment outcomes and adverse effects. In this article, we review a study examining the association of genetic variation in the cytochrome P450 2C9 enzyme with glycemic response to sulfonylureas in a large cohort of patients with Type 2 diabetes from the Genetics of Diabetes Audit and Research Tayside Study (Go-DARTS).

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20222813      PMCID： PMC2852129          DOI： 10.1586/erc.10.5

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN： 1477-9072


  24 in total

1.  Personalized medicine in the era of genomics.

Authors:  Wylie Burke; Bruce M Psaty
Journal:  JAMA       Date:  2007-10-10       Impact factor: 56.272

2.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

Authors:  Ewan R Pearson; Isabelle Flechtner; Pål R Njølstad; Maciej T Malecki; Sarah E Flanagan; Brian Larkin; Frances M Ashcroft; Iwar Klimes; Ethel Codner; Violeta Iotova; Annabelle S Slingerland; Julian Shield; Jean-Jacques Robert; Jens J Holst; Penny M Clark; Sian Ellard; Oddmund Søvik; Michel Polak; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2006-08-03       Impact factor: 91.245

3.  Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.

Authors:  Julia Kirchheiner; Jürgen Brockmöller; Ingolf Meineke; Steffen Bauer; Wolfgang Rohde; Christian Meisel; Ivar Roots
Journal:  Clin Pharmacol Ther       Date:  2002-04       Impact factor: 6.875

4.  Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

Authors:  Julia Kirchheiner; Steffen Bauer; Ingolf Meineke; Wolfgang Rohde; Verena Prang; Christian Meisel; Ivor Roots; Jürgen Brockmöller
Journal:  Pharmacogenetics       Date:  2002-03

5.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

6.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.

Authors:  Anna L Gloyn; Ewan R Pearson; Jennifer F Antcliff; Peter Proks; G Jan Bruining; Annabelle S Slingerland; Neville Howard; Shubha Srinivasan; José M C L Silva; Janne Molnes; Emma L Edghill; Timothy M Frayling; I Karen Temple; Deborah Mackay; Julian P H Shield; Zdenek Sumnik; Adrian van Rhijn; Jerry K H Wales; Penelope Clark; Shaun Gorman; Javier Aisenberg; Sian Ellard; Pål R Njølstad; Frances M Ashcroft; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2003-09       Impact factor: 19.112

Review 8.  Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease.

Authors:  Lee Park; Deborah Wexler
Journal:  Curr Opin Lipidol       Date:  2010-02       Impact factor: 4.776

9.  Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.

Authors:  Ewan R Pearson; Louise A Donnelly; Charlotte Kimber; Adrian Whitley; Alex S F Doney; Mark I McCarthy; Andrew T Hattersley; Andrew D Morris; Colin N A Palmer
Journal:  Diabetes       Date:  2007-05-22       Impact factor: 9.461

10.  HLA-B*5701 screening for hypersensitivity to abacavir.

Authors:  Simon Mallal; Elizabeth Phillips; Giampiero Carosi; Jean-Michel Molina; Cassy Workman; Janez Tomazic; Eva Jägel-Guedes; Sorin Rugina; Oleg Kozyrev; Juan Flores Cid; Phillip Hay; David Nolan; Sara Hughes; Arlene Hughes; Susanna Ryan; Nicholas Fitch; Daren Thorborn; Alastair Benbow
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245
View more
  3 in total

1.  Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of Gujarat.

Authors:  D Bhatt; N Chauhan; A Sharma; D Dhawan; R V Bhatt; S Phatak; H Padh
Journal:  Indian J Pharm Sci       Date:  2014-01       Impact factor: 0.975

2.  eMERGE Phenome-Wide Association Study (PheWAS) identifies clinical associations and pleiotropy for stop-gain variants.

Authors:  Anurag Verma; Shefali S Verma; Sarah A Pendergrass; Dana C Crawford; David R Crosslin; Helena Kuivaniemi; William S Bush; Yuki Bradford; Iftikhar Kullo; Suzette J Bielinski; Rongling Li; Joshua C Denny; Peggy Peissig; Scott Hebbring; Mariza De Andrade; Marylyn D Ritchie; Gerard Tromp
Journal:  BMC Med Genomics       Date:  2016-08-12       Impact factor: 3.063

3.  Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS).

Authors:  Harry L Hébert; Bridget Shepherd; Keith Milburn; Abirami Veluchamy; Weihua Meng; Fiona Carr; Louise A Donnelly; Roger Tavendale; Graham Leese; Helen M Colhoun; Ellie Dow; Andrew D Morris; Alexander S Doney; Chim C Lang; Ewan R Pearson; Blair H Smith; Colin N A Palmer
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.